March 4, 2019 – Acorda Therapeutics has announced the launch of its Inbrija™ (levodopa inhalation powder), which is U.S. FDA-approved to provide intermittent treatment for individuals with Parkinson’s disease who experience off episodes and are taking carbidopa/levodopa.
Over time, medication can lose its effectiveness in treating Parkinson’s disease. This leads to off episodes, during which patients experience increased motor function disruption. Inbrija can be taken on demand to address these off episodes. In clinical studies, patients experienced improvement of symptoms in 10 to 30 minutes. Recommended dosing is two capsules (84mg) inhaled as needed up to five times per day. Patients should not exceed 84mg per dose or 420mg per day.